Sentences with phrase «hiv vaccine candidates»

In January 2006, VaxGen granted to GSID a worldwide license to research, develop, manufacture, register, use, market, import, offer for sale, and sell its HIV vaccine candidates, including the AIDSVAX B / E vaccine.

The stock ran on the news, prompting VXGN to clarify yesterday that it «retains an option to obtain the exclusive right to manufacture, commercialize, and further develop the HIV vaccine candidates in the U.S., Europe, Japan and other countries that are members of the Organization of Economic Cooperation and Development» but «has no rights or obligations to manufacture or develop the vaccine candidates unless and until it exercises this option.»

Among other things, it features articles on new developments in HIV cure research, recent studies that show promise but also possible pitfalls of using adenovirus vectors in HIV vaccine candidates, and the funding crisis at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Although the efficacy in the Thai study was not high enough to warrant the vaccine's use as a public health tool, the results are helping scientists develop more effective HIV vaccine candidates.

The knowledge of the pathogenic mechanisms of infection and disease guide the development of intervention and prevention strategies and new HIV vaccine candidates.

This led to the establishment of international collaborations aimed at preclinical identification, development and selection of HIV vaccine candidates, such as NeutNet, a worldwide consortium dedicated to the standardisation of HIV neutralisation assays, and the Humoral Immunity Platform of EUROPRISE.

As the Global HIV Vaccine Product Manager for the US Army, Dr. Ake advances the development of HIV vaccine candidates in preclinical and early clinical studies.

In the new issue of IAVI Report we wrote about how researchers at the AIDS Vaccine 2010 conference in Atlanta discussed the limited window of opportunity for conducting clinical trials to test partially effective HIV prevention strategies, including HIV vaccine candidates and oral or topical antiretroviral pre-exposure prophylaxis (PrEP), in combination.

The HVTN's mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally.

W. Bogers: PhD in immunology and 20 years of experience with NHP models for the preclinical evaluation of HIV vaccine candidates as well as testing antivirals.

Now scientists at The Scripps Research Institute (TSRI) have developed a method to analyze the glycan shield on HIV's protective outer glycoprotein, developed as a potential HIV vaccine candidate.

According to Barouch, scientists are planning to advance this HIV vaccine candidate into clinical trials next year.

It will become the first HIV vaccine candidate developed at Fred Hutch to reach the clinical trial phase.

Dr. Leo Stamatatos, an immunologist in Fred Hutch's Vaccine and Infectious Disease Division, has received funding from the National Institutes of Health to begin manufacturing an HIV vaccine candidate designed to stimulate the production of broadly neutralizing antibodies and to test the experimental vaccine in human clinical trials.

2009 — Developed an MVA HIV Vaccine Candidate — MHRP and NIAID researchers developed a new HIV vaccine, specific to the strain of HIV circulating in Southeast Asia that is expressed in a modified smallpox virus vector (MVA).

Not exact matches

The next step in this research is to analyze the glycan composition and glycan - free sites on the natural, or «native,» form of HIV, not just an HIV - like vaccine candidate.

«HIV - 1 specific IgG3 is one biomarker that can be evaluated in further vaccine candidates.

It provides a specific way to benchmark HIV - 1 vaccine candidates against the one partially efficacious vaccine to date.»

«We learned in this study that grabbing hold of these glycans can be a very important early step in an effective immune response to HIV, and with this knowledge, we believe we can design better candidate vaccines,» said principal investigator Dennis R. Burton, professor of immunology and microbiology at TSRI.

«New clues to how a successful HIV vaccine could work: Sugar molecules on HIV envelope protein are likely target for future candidate vaccines.»

In a previously published paper, Barouch and colleagues, including Colonel Nelson L. Michael, MD, PhD, director of the Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) and Stephen Thomas, MD, Upstate Medical University, State University of New York, demonstrated that three different vaccine candidates provided robust protection against Zika virus in both mice and rhesus monkeys.

The protein fragment of the vaccine candidate comes from gp120, a protein that covers HIV like a protective envelope.

«We previously showed that adenovirus vector - based HIV - 1 vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical vaccine candidates offered partial protection against SIV when given alone,» said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical Vaccine Research at BIDMC and professor of medicine at Harvard Medical School.

Researchers at the University of Maryland and Duke University have designed a novel protein - sugar vaccine candidate that, in an animal model, stimulated an immune response against sugars that form a protective shield around HIV.

Wang and collaborators designed a vaccine candidate using an HIV protein fragment linked to a sugar group.

Next, the researchers injected the protein - sugar vaccine candidate into rabbits and found that the rabbits» immune systems produced antibodies that physically bound to gp120 found in four dominant strains of HIV in circulation today.

Injecting rabbits with a vaccine candidate that contained the protein fragment without the sugar group resulted in antibodies that primarily bound to gp120 from only one HIV strain.

The researchers» next steps will be to conduct longer - term studies in combination with other vaccine candidates, hone in on what areas of gp120 the antibodies are binding to and determine how they can increase the antibodies» effectiveness at neutralizing HIV.

When injected into rabbits, the vaccine candidate stimulated antibody responses against the sugar shield in four different HIV strains.

TNA8: BPRC will provide access to macaques for immunogenicity / adjuvanticity evaluation of vaccine candidates for malaria, tuberculosis, HIV, influenza, West Nile virus or dengue virus, with up to three (prime - boost) immunisation events.

So far, in the 30 years since the AIDS virus was identified, only one vaccine candidate has shown any protection at all, reducing the risk of contracting HIV by 31 percent.

Research Trials The HVTN also plans to test other HIV vaccine regimens in Southern Africa in a parallel research track using multiple vaccine candidates.

Before joining IDRI, Tracey worked as a Protocol Development Manager with the HIV Vaccine Trials Network at the Fred Hutchinson Cancer Research Center where she led multi-disciplinary teams in the design and implementation of clinical trials evaluating candidate HIV and tuberculosis vaccines.

Therefore the group: i) characterizes the specificity of these antibody responses to identify relevant targets for a vaccine; ii) developes new approaches to test antibody responses; and iii) adoptes the immunological analysis in preclinical (in rabbits and macaques) and clinical vaccines studies to identify predictive signatures for the development and prioritization of new HIV - 1 vaccine candidates.

A004 is a phase II study of an HIV candidate vaccine Ad26 prime with MVA and protein boost funded and sponsored by Janssen, a division of J&J.

MHRP scientists, working with NIAID, have developed an attenuated viral vector — modified vaccinia Ankara — vaccine candidate, MVA - CMDR (HIV - 1 CM235 env / CM240 gag - pol).

Though a preventative vaccine for HIV does not yet exist, NIAID oversees a robust research program to develop and evaluate vaccine candidates.

In 2009, a vaccine candidate studied in a trial of over 16,000 individuals in Thailand was the first to modestly protect against HIV infection.

MHRP's expansion of research activities into Mozambique provides scientists the opportunity to test future vaccine candidates against the predominant HIV subtype (C) circulating in this part of the world.

Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost vaccine candidates initially tested in the RV144 trial in Thailand — the only HIV vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai volunteers.

Results from an initial study combining a microbicide candidate and experimental vaccine are promising enough to at least keep Imperial College virologist Robin Shattock coming back for more in pursuing what could be a novel move in preventing HIV infection.